Cancer Radiotherapie最新文献

Role of radiotherapy in the treatment of primary vaginal cancer: Recommendations of the Société française de radiothérapie oncologique, 2025 update 放射治疗在原发阴道癌治疗中的作用：放射与肿瘤学会的建议，2025年更新。

IF 1.4 4区医学

Cancer Radiotherapie Pub Date : 2025-09-16 DOI: 10.1016/j.canrad.2025.104725

Cyrus Chargari , Anne Ducassou , Camille Roukoz , François Lucia , Adeline Petit , Abel Cordoba , Caroline Lafond , Sophie Renard , Alexandre Escande

引用次数: 0

Role of radiotherapy in the management of vulvar cancer: Recommendations of the Société française de radiothérapie oncologique, 2025 update 放射治疗在外阴癌治疗中的作用：放射与肿瘤学会的建议，2025年更新。

IF 1.4 4区医学

Cancer Radiotherapie Pub Date : 2025-09-16 DOI: 10.1016/j.canrad.2025.104726

Cyrus Chargari , Sophie Renard , Marie-Adélaïde Ossedat , Abel Cordoba , François Lucia , Adeline Petit , Sylvain Demontoy , Isabelle Flandin , Caroline Lafond , Anne Ducassou , Alexandre Escande

引用次数: 0

Management of cervical lymphadenopathies of unknown primary cancer 未知原发癌的宫颈淋巴结病的处理。

IF 1.4 4区医学

Cancer Radiotherapie Pub Date : 2025-09-16 DOI: 10.1016/j.canrad.2025.104721

Xavier Musset , Idriss Troussier , Nolwenn Delaby , Pierre Blanchard , Yoann Pointreau , Sébastien Thureau

引用次数: 0

Radiotherapy for patients with pacemakers and implantable cardioverter defibrillators: A review of the recommendations and practical application 心脏起搏器和植入式心律转复除颤器患者的放疗：建议和实际应用综述。

IF 1.4 4区医学

Cancer Radiotherapie Pub Date : 2025-09-16 DOI: 10.1016/j.canrad.2025.104717

Sofiane Allali , Pierre Loap , Adnan Shrebati , Thomas Lacornerie , Youlia Kirova , Frédéric Sebag , Kim-I. Cao

引用次数: 0

Tumour and normal tissue radiosensitivity: 2025 update 肿瘤和正常组织放射敏感性：2025年更新

IF 1.4 4区医学

Cancer Radiotherapie Pub Date : 2025-09-11 DOI: 10.1016/j.canrad.2025.104720

Ariane Lapierre , Jeanne Monge-Cadet , Muriel Brengues , Igor Bessières , Laurent Quéro , Céline Mirjolet , Olivier Riou

{"title":"Tumour and normal tissue radiosensitivity: 2025 update","authors":"Ariane Lapierre , Jeanne Monge-Cadet , Muriel Brengues , Igor Bessières , Laurent Quéro , Céline Mirjolet , Olivier Riou","doi":"10.1016/j.canrad.2025.104720","DOIUrl":"10.1016/j.canrad.2025.104720","url":null,"abstract":"<div><div>The personalization of oncology and radiation treatments is becoming increasingly crucial in patient care. Over the past few decades, numerous assays have been developed to predict tumour response and assess the risk of radiation-induced toxicity. These tests have not yet been integrated into routine clinical practice, but recent advances in radiation oncology are paving the way for personalized strategies that consider both tumour recurrence risk and normal tissue reactions. Regarding tumour radiosensitivity prediction, no tests are currently in clinical use, although the radiosensitivity index and Genome-based Model for Adjusting Radiotherapy Dose assays appear to be the most promising, with level II evidence. Development of radiomics has also made it possible to envisage new biomarkers. Prospective studies are ongoing. For normal tissue radiosensitivity prediction, single nucleotide polymorphims in prostate cancer and head and neck cancer patients, and the radiation-induced CD8 T-lymphocyte apoptosis assay for breast and prostate cancers are supported by level I evidence. These tests can be offered prior to the initiation of radiotherapy to tailor treatments based on both tumour and normal tissue radiosensitivity risks.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104720"},"PeriodicalIF":1.4,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145045189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Radiotherapy of skin cancers 皮肤癌放射治疗

IF 1.4 4区医学

Cancer Radiotherapie Pub Date : 2025-09-11 DOI: 10.1016/j.canrad.2025.104724

Emmanuelle Le Fur , Matthieu Pallandre , Adeline Pêtre , Pierre Clavère , Laurent Quéro , Emmanuel Rio , Véronique Bodez , Christophe Hennequin

引用次数: 0

Radiotherapy for laryngeal cancers: 2025 update 喉癌放疗：2025年更新

IF 1.4 4区医学

Cancer Radiotherapie Pub Date : 2025-09-11 DOI: 10.1016/j.canrad.2025.104727

Audrey Maury , Mathieu Bosset , Alexandre Coutte , Michel Lapeyre , Nolwenn Delaby , Pierre Blanchard , Yoann Pointreau , Julian Biau

{"title":"Radiotherapy for laryngeal cancers: 2025 update","authors":"Audrey Maury , Mathieu Bosset , Alexandre Coutte , Michel Lapeyre , Nolwenn Delaby , Pierre Blanchard , Yoann Pointreau , Julian Biau","doi":"10.1016/j.canrad.2025.104727","DOIUrl":"10.1016/j.canrad.2025.104727","url":null,"abstract":"<div><div>We present the updated recommendations of the Société française de radiothérapie oncologique (SFRO; the French society of radiation oncology) regarding the radiotherapy management of laryngeal cancers. Clinical examination in a seated position and nasofibroscopy are essential for accurately assessing laryngeal mobility, a crucial parameter in the therapeutic decision-making process for glottic cancer. In early-stage cancers, treatment selection depends on multiple factors and requires thorough consideration and multidisciplinary discussion. Between surgery and radiotherapy, the decision can be personalized to achieve an optimal balance between tumour control and the preservation of laryngeal function. In advanced-stage laryngeal tumours, the therapeutic approach is mainly based on two strategies: concomitant chemoradiotherapy or induction chemotherapy followed by chemoradiotherapy. However, in some cases where these approaches are not feasible, the treatment relies on upfront total laryngectomy, often followed by adjuvant therapy. With the exception of early-stage glottic tumours, where hypofractionation has proven its efficacy, there is no formal indication to modify the standard fractionation regimen. Due to the movements induced by respiration and swallowing, laryngeal mobility must be taken into account. Three-dimensional volumetric imaging is the gold standard for ensuring accurate daily patient positioning and monitoring weight loss. The follow-up of laryngeal cancers is crucial for the early detection of potential recurrences and for adjusting oncological management when necessary. It also plays a key role in patient rehabilitation, ensuring the best possible preservation of vocal and respiratory functions to optimize quality of life.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104727"},"PeriodicalIF":1.4,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145045190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Role of radiotherapy in the management of primary renal cell carcinoma: Recommendations from the Société française de radiothérapie oncologique (SFRO, the French society for radiation oncology) 放射治疗在原发性肾细胞癌治疗中的作用：来自法国放射肿瘤学会（SFRO）的建议

IF 1.4 4区医学

Cancer Radiotherapie Pub Date : 2025-09-10 DOI: 10.1016/j.canrad.2025.104713

Nicolas Benziane-Ouaritini , Jennifer Le Guevelou , Stéphane Supiot , Mario Terlizzi , Olivier Chapet , Idir Ouzaid , David Pasquier , Vincent Marchesi , Igor Latorzeff , Paul Sargos

{"title":"Role of radiotherapy in the management of primary renal cell carcinoma: Recommendations from the Société française de radiothérapie oncologique (SFRO, the French society for radiation oncology)","authors":"Nicolas Benziane-Ouaritini , Jennifer Le Guevelou , Stéphane Supiot , Mario Terlizzi , Olivier Chapet , Idir Ouzaid , David Pasquier , Vincent Marchesi , Igor Latorzeff , Paul Sargos","doi":"10.1016/j.canrad.2025.104713","DOIUrl":"10.1016/j.canrad.2025.104713","url":null,"abstract":"<div><div>Renal cell carcinoma represents the 14th most frequent tumour worldwide, but its incidence is increasing partly due to incidental diagnoses. As a result, these tumours are diagnosed in patients at an increasingly advanced age, often frail and with comorbidities. Most renal cell carcinoma cases are clear cell carcinoma (80 %), with papillary tumours being the second most frequent histological subtype. The standard of care for localized RCC is surgery, with partial nephrectomy or radical nephrectomy being recommended for T1 and T2 tumours, respectively. Thermoablative strategies have been developed over the past decade for patients who are not amenable to surgery and/or with impaired renal function. Active surveillance remains an alternative in the case of small low-grade renal cell carcinoma. Recent research has evaluated stereotactic ablative body radiotherapy as a well-tolerated and effective treatment for small renal tumours essentially for the management of both T1a and T1b tumours. This article aims to report the recommendations of the Société française de radiothérapie oncologique (SFRO, the French society for radiation oncology) on the role of radiotherapy in the management of localized renal cell carcinoma. These guidelines describe both treatment planning modalities, target volumes, and follow-up procedures. They also focus on the impact of radiotherapy on renal function, and the specific dosimetric constraints to be implemented.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104713"},"PeriodicalIF":1.4,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145027042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rectal cancer radiotherapy: 2025 update 直肠癌放疗：2025年更新

IF 1.4 4区医学

Cancer Radiotherapie Pub Date : 2025-09-10 DOI: 10.1016/j.canrad.2025.104722

Alice Blache , Marina Jolnerowski , Jérome Durand-Labrunie , Nicolas Meillan , Igor Bessières , Benjamin Schipman , Florence Huguet , Véronique Vendrely

{"title":"Rectal cancer radiotherapy: 2025 update","authors":"Alice Blache , Marina Jolnerowski , Jérome Durand-Labrunie , Nicolas Meillan , Igor Bessières , Benjamin Schipman , Florence Huguet , Véronique Vendrely","doi":"10.1016/j.canrad.2025.104722","DOIUrl":"10.1016/j.canrad.2025.104722","url":null,"abstract":"<div><div>We present the updated recommendations of the Société française de radiothérapie oncologique (SFRO, the French society for oncological radiotherapy) for rectal cancer radiotherapy. The standard treatment for locally advanced rectal cancer consists in chemoradiotherapy followed by radical surgery with total mesorectal resection and adjuvant chemotherapy according to nodal status. Although this strategy efficiently reduced local recurrences rates below 5 % in expert centres, functional sequelae could not be avoided resulting in 20 to 30 % morbidity rates. The early introduction of neoadjuvant chemotherapy followed by chemoradiation has proven to be beneficial in recent trials, in terms of recurrence-free and metastasis-free survivals becoming the new standard treatment strategy. Complete pathological responses were obtained in 15 % of tumours treated by chemoradiotherapy, even reaching up to 30 % of tumours when neoadjuvant chemotherapy is associated to chemoradiotherapy. These good results question the relevance of systematic radical surgery in good responders. Personalized therapeutic strategies are now possible by improved imaging modalities with circumferential margin assessed by magnetic resonance imaging, by intensity-modulated radiotherapy and by refining surgical techniques, and contribute to morbidity reduction. Keeping the same objectives, ongoing trials are now evaluating therapeutic de-escalation strategies, in particular rectal preservation for good responders after neoadjuvant treatment or radiotherapy omission in selected cases.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104722"},"PeriodicalIF":1.4,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145026259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Management of metallic implants in radiotherapy: 2025 update 放射治疗中金属植入物的管理：2025年更新

IF 1.4 4区医学

Cancer Radiotherapie Pub Date : 2025-09-10 DOI: 10.1016/j.canrad.2025.104723

Adnan Shrebati , Clara Le Fèvre , Thomas Lacornerie , Georges Noël , Delphine Antoni , Pierre Loap , Youlia Kirova

引用次数: 0